Hepatitis C
New HCV NS5A Inhibitor ACH-3102 Enters Clinical Trials, Gets FDA Fast-Track Status
- Details
- Category: HCV Treatment
- Published on Wednesday, 16 May 2012 00:00
Achillion's second-generation hepatitis C virus (HCV) NS5A inhibitor ACH-3102 is now undergoing Phase 1 clinical testing and has been granted "Fast Track" status, a U.S. Food and Drug Administration designation for experimental therapies that address urgent unmet need, the company announced this week.
EASL: Ribavirin Dose Reduction Is Effective for Managing Anemia in Patients Using Boceprevir or Telaprevir
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 May 2012 00:00
Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th International Liver Congress (EASL 2012) this week in Barcelona. A related study found that ribavirin reduction also did not impair cure rates with telaprevir (Incivek).
EASL: Promising Findings for Therapeutic Hepatitis C Vaccine TG4040
- Details
- Category: HCV Treatment
- Published on Wednesday, 02 May 2012 00:00
An investigational hepatitis C virus (HCV) therapeutic vaccine significantly improved the likelihood of sustained response to interferon-based therapy, according to a proof-of-concept study reported at the 47th International Liver Congress (EASL 2012) this week in Barcelona.
EASL: MicroRNA Miravirsen Looks Safe and Effective for Genotype 1 Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 04 May 2012 00:00
Miravirsen, the first microRNA therapy for hepatitis C, was well-tolerated and demonstrated prolonged antiviral activity lasting past the end of dosing in a proof-of-concept study of previously untreated HCV genotype 1 patients presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL: Boceprevir a Useful Option for Patients Who Did Not Respond to Earlier Hepatitis C Therapy
- Details
- Category: HCV Treatment
- Published on Friday, 27 April 2012 00:00
A regimen of boceprevir with pegylated interferon and ribavirin achieved cure rates of between 40% and 68% in patients who did not respond to a previous course of hepatitis C therapy, data presented to the 47th International Liver Congress (EASL 2012) in Barcelona last week show.
May Is Hepatitis Awareness Month
- Details
- Category: Hepatitis B
- Published on Wednesday, 02 May 2012 00:00
May is designated as Hepatitis Awareness Month in the U.S., an opportunity to promote better understanding of and encourage testing and care for viral hepatitis.
EASL: Abbott Interferon-Free HCV Combinations Show Early Promise for Untreated Patients
- Details
- Category: HCV Treatment
- Published on Friday, 27 April 2012 00:00
Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naive patients presented last week at the 47th International Liver Congress (EASL 2012) in Barcelona.
EASL: BI 201335 + BI 207127 + Ribavirin Shows Good Efficacy, Including Hepatitis C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Wednesday, 02 May 2012 00:00
An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C patients, with favorable safety and efficacy among people with liver cirrhosis, researchers reported at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL: Alisporivir + Ribavirin Is Effective for Hepatitis C, but Pancreatitis Remains a Concern
- Details
- Category: HCV Treatment
- Published on Monday, 23 April 2012 00:00
Alisporivir (formerly Debio 025) in interferon-free combinations cured more than 80% of patients with hepatitis C virus (HCV) genotype 2 or 3, researchers reported the 47th International Liver Congress (EASL 2012) last week in Barcelona. The drug has been put on hold, however, due to a small number of recipients developing life-threatening pancreas inflammation.
More Articles...
- EASL: Simeprevir (TMC435) Improves Response Rates for Difficult-to-Treat Hepatitis C Patients
- EASL: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
- EASL: GS-7977, Daclatasvir, and Asunaprevir Look Good in Interferon-Free Regimens for Hepatitis C
- EASL: International Liver Congress Focuses on Hepatitis C Treatment, Metabolic Liver Disease
- EASL: Interferon Lambda as Effective as Alfa for Hepatitis C but with Much Better Safety Profile
